Aprea Therapeutics Safety Review Committee Endorses Dosing Patients With ATRN-119 In ABOYA-119 Clinical Trial

5/28/24 8:48:46 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $APRE alert in real time by email

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential

On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024

Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed

Get the next $APRE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APRE

Date	Price Target	Rating	Analyst
8/20/2021		Neutral → Underweight	JP Morgan
8/16/2021		Buy → Hold	Berenberg
8/16/2021	$6.00 → $4.00	Neutral	HC Wainwright & Co.
8/13/2021	$6.00 → $5.00	Sector Perform	RBC Capital
8/13/2021	$5.00 → $3.00	Equal-Weight → Underweight	Morgan Stanley

More analyst ratings

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash equivalents as of September 30, 2024 with cash runway for at least twelve months DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the third quarter ended September 30, 2024, and provided a bu
11/7/24 8:00:00 AM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. Preliminary results to date demonstrate APR-1051 is safe and well-tolerated with no hematologic toxicity DOYLESTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented today at the EORTC-NCI-AACR Symposium on Molecular Targets
10/23/24 8:30:00 AM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024. Presentation Details Session:Precision and Immune Oncology PanelDate/ time:Wednesday, October 16, 2:00 - 3:00 PM ET Session:Fireside ChatDate/ time:Thursday, October 17, 3:30 - 4:00 PM ET This conference will be hosted live on M-Vest. To access the above presentations, sign up to become an M-Ve
10/14/24 8:30:00 AM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care

$APRE
Financials

Live finance-specific insights

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o
8/11/22 4:15:00 PM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash
5/16/22 9:21:33 AM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i
8/5/21 5:00:00 PM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care

$APRE
Leadership Updates

Live Leadership Updates

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag
10/9/24 8:30:00 AM ET
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de
10/1/24 8:30:00 AM ET
$APRE
$IART
$OMGA
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Alltrna Announces Updates to Its Board of Directors
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
7/17/24 8:00:00 AM ET
$APRE
$CYTK
$EVLO
$FHTX
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)

Aprea Therapeutics Safety Review Committee Endorses Dosing Patients With ATRN-119 In ABOYA-119 Clinical Trial

Chat with this insight

Recent Analyst Ratings for $APRE

$APRE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Duey Marc sold $29,583 worth of shares (6,462 units at $4.58), decreasing direct ownership by 3% to 233,651 units (SEC Form 4)

President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

$APRE Market Insights

Live Market Insights

$APRE Press Releases

Fastest customizable press release news feed in the world

$APRE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$APRE Large Ownership Changes

This live feed shows all institutional transactions in real time.

$APRE SEC Filings

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

Aprea Therapeutics To Host Virtual KOL Event On June 24, 2024, To Discuss APR-1051, A Selective Oral WEE1 Inhibitor

Aprea Therapeutics To Host Virtual KOL Event On APR-1051

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

President/CEO Gilad Oren bought $725 worth of shares (250 units at $2.90), increasing direct ownership by 0.08% to 332,895 units (SEC Form 4)

SEC Form SC 13G filed by Aprea Therapeutics Inc.

SEC Form SC 13G filed by Aprea Therapeutics Inc.

SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

SEC Form SCHEDULE 13G filed by Aprea Therapeutics Inc.

Aprea Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 424B5 filed by Aprea Therapeutics Inc.

$APRE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Aprea Therapeutics downgraded by JP Morgan

Aprea Therapeutics downgraded by Berenberg

HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

$APRE Financials

Live finance-specific insights

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

$APRE Leadership Updates

Live Leadership Updates

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Alltrna Announces Updates to Its Board of Directors

Recent Analyst Ratings for
$APRE

$APRE
Insider Trading

$APRE
Market Insights

$APRE
Press Releases

$APRE
Insider Purchases

$APRE
Large Ownership Changes

$APRE
SEC Filings

$APRE
Analyst Ratings

$APRE
Financials

$APRE
Leadership Updates